权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Role of PTPN11 in Myelofibrosis

PTPN11 在骨髓纤维化中的作用

基本信息

批准号：
10324574
负责人：
Golam Mohi
金额：
$ 39.92万
依托单位：
UNIVERSITY OF VIRGINIA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-01-01 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10324574
关键词：
Animal Model Applications Grants Bone Marrow Cell Line Cell Lineage Cell Proliferation Cells Data Deposition Development Disease remission Exhibits Extramedullary Hematopoiesis Fibrosis Frequencies Gene Expression Profiling Genes Goals Growth Hematopoietic Hematopoietic stem cells Hemorrhagic Thrombocythemia Human JAK1 gene JAK2 gene Knock-in Knock-in Mouse Knock-out Lead LoxP-flanked allele MPL gene Mediating Megakaryocytopoieses Molecular Mus Mutation Myelofibrosis Myelogenous Myeloproliferative disease PTPN11 gene Pathogenesis Patients Penetrance Pharmacology Phase I/II Clinical Trial Placebos Play Polycythemia Vera Pre-Clinical Model Production Protein Tyrosine Kinase Protein Tyrosine Phosphatase Role Signal Transduction Splenomegaly Testing Therapeutic Time Tissues base calreticulin chemotherapy design efficacy testing expectation inhibitor insight knock-down mouse model mutant new therapeutic target novel novel therapeutic intervention prevent small hairpin RNA stem cells targeted treatment therapeutic target transcriptome sequencing

项目摘要

Title: The Role of PTPN11 in Myelofibrosis Project Summary/Abstract Myelofibrosis (MF) is the most severe form of myeloproliferative neoplasm (MPN), characterized by deposition of fibrous tissues in the bone marrow, abnormal megakaryopoiesis, and extramedullary hematopoiesis. The median survival for patients with MF is ~5 years. A somatic activating V617F mutation in the Janus Kinase 2 (JAK2V617F) has been found in 50-60% patients with MF. Additional mutations in the genes encoding thrombopoietin receptor (MPL) and calreticulin (CALR) have been found in MF but at a lower frequency than JAK2V617F. Ruxolitinib, a JAK1/JAK2 inhibitor, has been approved for treatment of MF. Although Ruxolitinib can reduce splenomegaly, it failed to produce disease remission or prevent fibrosis in patients with MPN/MF. It has already become clear that current chemotherapies including JAK2 inhibitors are not sufficient to cure MPN/MF. So, there is a critical need to identify new therapeutic target(s) and develop novel targeted therapies for MF. In preliminary studies, we have identified protein tyrosine phosphatase PTPN11 as a potential therapeutic target in MF. We have found that PTPN11 is constitutively phosphorylated in mouse and human MPN hematopoietic cells/progenitors. Knockdown of PTPN11 significantly inhibits proliferation of cells expressing JAK2V617F. In preliminary studies, using conditional PTPN11 knockout and JAK2V617F knock-in mice, we have observed that deletion of PTPN11 prevents the development of PV and markedly inhibits myelofibrosis. We also have observed that pharmacologic inhibition of PTPN11 significantly inhibits the growth of JAK2V617F-positive MPN cells and markedly reduces the bone marrow fibrosis in JAK2V617F knock-in mice. So, we hypothesize that PTPN11 may play an important role in the pathogenesis of MF, and inhibition of PTPN11 might be useful for treatment of MPN/MF. To test our hypothesis, we have proposed three specific aims. In Aim 1, we will investigate the role of PTPN11 in the pathogenesis of myelofibrosis (MF). In Aim 2, we will determine the efficacy of PTPN11 inhibition against MPN cells/progenitors and animal models of MPN/MF. In Aim 3, we will determine the mechanism by which PTPN11 depletion or inhibition blocks the development/ progression of MPN/MF. Our proposed studies will provide the first demonstration that PTPN11 plays an important role in the pathogenesis of MF and inhibition of PTPN11 is a novel therapeutic approach in MF. We will also have mechanistic understanding on how PTPN11 contributes to the development of MF. Results from these studies should lead to the design of a Phase I/II clinical trial involving PTPN11 inhibitor for treatment of MPN/MF.

标题：PTPN 11在骨髓纤维化中的作用项目总结/摘要骨髓纤维化（MF）是骨髓增生性肿瘤（MPN）中最严重的一种，其特征是骨髓纤维组织增生异常、异常巨核细胞生成和髓外造血。的 MF患者的中位生存期约为5年。Janus激酶2的体细胞激活V617 F突变在50-60%的MF患者中发现了JAK 2 V617 F。基因编码的其他突变血小板生成素受体（MPL）和钙网蛋白（CALR）在MF中被发现，但频率低于 JAK2V617F. Ruxolitinib是一种JAK 1/JAK 2抑制剂，已被批准用于治疗MF。虽然Ruxolitinib 但不能缓解MPN/MF患者的病情或预防纤维化。它已经很清楚，目前的化疗，包括JAK 2抑制剂是不足以治愈 MPN/MF。因此，寻找新的治疗靶点，开发新的靶向治疗方法，成为当前研究的热点对于MF。在初步研究中，我们已经确定蛋白酪氨酸磷酸酶PTPN 11作为一种潜在的 MF的治疗靶点。我们已经发现PTPN 11在小鼠和人类中是组成性磷酸化的， MPN造血细胞/祖细胞。PTPN 11的敲低显著抑制细胞增殖表达JAK 2 V617 F。在初步研究中，使用条件性PTPN 11敲除和JAK 2 V617 F敲入，在小鼠中，我们观察到PTPN 11的缺失阻止了PV的发展，并显著抑制了PV的发生。骨髓纤维化我们还观察到PTPN 11的药理学抑制显著抑制了细胞的生长， JAK 2 V617 F-阳性MPN细胞的表达，并显著降低JAK 2 V617 F基因敲入的骨髓纤维化小鼠因此，我们推测PTPN 11可能在MF的发病机制中起重要作用，并且抑制PTPN 11的表达可能是MF发病的重要机制之一。 PTPN 11可能对MPN/MF的治疗有一定的作用。为了验证我们的假设，我们提出了三个具体的假设。目标。在目的1中，我们将研究PTPN 11在骨髓纤维化（MF）发病机制中的作用。在目标2中，将确定PTPN 11抑制MPN细胞/祖细胞和MPN/MF动物模型的功效。在目标3中，我们将确定PTPN 11耗尽或抑制阻断发展的机制。 MPN/MF的进展。我们提出的研究将首次证明PTPN 11在肿瘤发生中起着重要作用。 PTPN 11在MF发病机制中的重要作用和抑制PTPN 11是MF的一种新的治疗方法。我们还将对PTPN 11如何促进MF的发展有机械的理解。结果这些研究应该导致设计一个I/II期临床试验，涉及PTPN 11抑制剂治疗 MPN/MF。